Pfizer (NYSE: PFE) is scheduled to report its Q3 2022 results on Tuesday, November 1, and we expect it to post revenue and earnings above the consensus estimates. Its Covid-19 vaccine and the ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported solid financial results for third-quarter 2022 and updated certain components of 2022 financial guidance (4). Pfizer raised the lower end of ...

Pfizer has reached a $5.4 billion deal to buy Global Blood Therapeutics, a company with one commercialized therapy for sickle cell disease and a pipeline of additional drugs in various stages of ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance (4). Pfizer reaffirmed its ...

Nov 1 (Reuters) - Pfizer Inc (PFE.N), opens new tab on Tuesday raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion, and said new deals and drugs in development ...

Pfizer Inc. emerged from the Covid-19 pandemic as the world’s most visible drugmaker, but its success has left investors impatient for an encore. The windfall from the pharmaceutical giant’s Covid ...

Good day, everyone, and welcome to Pfizer’s Fourth Quarter 2022 Earnings Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, Senior ...

The medication could soon be approved to treat an addressable market of nearly 200,000 patients. Etrasimod, intended to treat ulcerative colitis, could haul in $1 billion in annual sales for Pfizer.

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...